Distinct Roles of Parafibromin in the Extracellular Environment, Cytoplasm and Nucleus of Osteosarcoma Cells

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2016 Jun 28

PMID 27347351

Citations 7

Authors

Jia-Jun Zhu

Yan Cui

Kai Cui

Xi Li

Zhi-Yu Zhang

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor. Parafibromin-inactivating mutations have been reported in various malignancies. In this study, the effects and relevant mechanisms of ectopic parafibromin expression were identified in the extracellular environment, cytoplasm and nucleus of OS cells. Our results indicate that parafibromin located in the nucleus can induce apoptosis and G1 phase arrest in OS cells. Parafibromin was found to suppress the MEK/ERK and PI3K/AKT signaling pathways, leading to activation of caspase 3 and caspase 9. Overall, these studies demonstrate the anti-tumor activity of parafibromin in the OS cell line, and provide insight into relevant mechanisms that may lead to novel treatments for OS.

Citing Articles

Association Between Parafibromin Expression and Presence of Brown Tumors and Jaw Tumors in Patients with Primary Hyperparathyroidism: Series of Cases with Review of the Literature.

Popow M, Kaszczewska M, Goralska M, Kaszczewski P, Skwarek-Szewczyk A, Chudzinski W Am J Case Rep. 2022; 23:e936135.

PMID: 36271606 PMC: 9597261. DOI: 10.12659/AJCR.936135.

The clinicopathological and prognostic significances of CDC73 expression in breast cancer: A pathological and bioinformatics analysis.

E Y, Xue H, Zhang C, Zhao M, Zheng H Histol Histopathol. 2022; 38(4):453-465.

PMID: 36255176 DOI: 10.14670/HH-18-534.

The roles of the tumor suppressor parafibromin in cancer.

Zheng H, Xue H, Zhang C Front Cell Dev Biol. 2022; 10:1006400.

PMID: 36211470 PMC: 9532749. DOI: 10.3389/fcell.2022.1006400.

Parafibromin Is Highly Expressed in Hepatocellular Carcinoma and Its Expression Correlates with Poor Prognosis.

Kim M J Clin Med. 2022; 11(7).

PMID: 35407381 PMC: 9000084. DOI: 10.3390/jcm11071773.

The clinicopathological and prognostic significances of expression in cancers: a bioinformatics analysis.

Zheng H, Gong B, Zhao S Oncotarget. 2017; 8(56):95270-95279.

PMID: 29221126 PMC: 5707020. DOI: 10.18632/oncotarget.20446.

References

Carpten J, ROBBINS C, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J . HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002; 32(4):676-80. DOI: 10.1038/ng1048. View

Bibollet-Bahena O, Almazan G . IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways. J Neurochem. 2009; 109(5):1440-51. DOI: 10.1111/j.1471-4159.2009.06071.x. View

Lin L, Zhang J, Panicker L, Simonds W . The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc Natl Acad Sci U S A. 2008; 105(45):17420-5. PMC: 2582266. DOI: 10.1073/pnas.0710725105. View

Zhang Z, Yang X, Huang K, Ren L, Gou W, Shen D . The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas. Tumour Biol. 2015; 36(12):9487-97. DOI: 10.1007/s13277-015-3618-5. View

Bielack S, Kempf-Bielack B, Delling G, Exner G, Flege S, Helmke K . Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20(3):776-90. DOI: 10.1200/JCO.2002.20.3.776. View

Truran P, Johnson S, Bliss R, Lennard T, Aspinall S . Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014; 38(11):2845-54. DOI: 10.1007/s00268-014-2700-2. View

Zheng H, Takahashi H, Li X, Hara T, Masuda S, Guan Y . Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Virchows Arch. 2007; 452(2):147-55. PMC: 2233709. DOI: 10.1007/s00428-007-0551-z. View

Zheng H, Wei Z, Xu X, Nie X, Yang X, Takahashi H . Parafibromin expression is an independent prognostic factor for colorectal carcinomas. Hum Pathol. 2011; 42(8):1089-102. DOI: 10.1016/j.humpath.2010.10.024. View

Hahn M, Marsh D . Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene. 2005; 24(41):6241-8. DOI: 10.1038/sj.onc.1208778. View

10.

Rather M, Swamy S, Gopinath K, Kumar A . Transcriptional repression of tumor suppressor CDC73, encoding an RNA polymerase II interactor, by Wilms tumor 1 protein (WT1) promotes cell proliferation: implication for cancer therapeutics. J Biol Chem. 2013; 289(2):968-76. PMC: 3887219. DOI: 10.1074/jbc.M113.483255. View

11.

Ando K, Heymann M, Stresing V, Mori K, Redini F, Heymann D . Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 2013; 5(2):591-616. PMC: 3730336. DOI: 10.3390/cancers5020591. View

12.

Cui C, Lal P, Master S, Ma Y, Baradet T, Bing Z . Expression of parafibromin in major renal cell tumors. Eur J Histochem. 2013; 56(4):e39. PMC: 3567758. DOI: 10.4081/ejh.2012.e39. View

13.

Jo J, Chung T, Youn H, Yoo J . Cytoplasmic parafibromin/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis. Nat Commun. 2014; 5:5433. DOI: 10.1038/ncomms6433. View

14.

Xia P, Wang W, Xu X, Wang J, Takano Y, Zheng H . Parafibromin expression in lung normal tissue and carcinoma: its comparison with clinicopathological parameters of carcinoma. Histol Histopathol. 2011; 26(8):1039-47. DOI: 10.14670/HH-26.1039. View

15.

Shankar S, Ganapathy S, Srivastava R . Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res. 2008; 14(21):6855-66. DOI: 10.1158/1078-0432.CCR-08-0903. View